#883: How to Legalize Medical Psychedelics in Your Country — Tania de Jong on The Playbook Behind Australia's World-First Breakthrough

What It Covers

Tania de Jong, co-founder of Mind Medicine Australia, details the eight-year campaign that made Australia the first country to legally permit psilocybin and MDMA prescriptions for psychiatric conditions in February 2023. She outlines the specific strategies — regulatory submissions, coalition building, clinician training, and payor recruitment — that outsiders with no medical background used to achieve this regulatory breakthrough.

Key Questions Answered

• •Regulatory Persistence via Documented Objections: When the Therapeutic Goods Administration rejected rescheduling applications at both interim and final stages, Mind Medicine Australia used the TGA's mandatory written reasons for rejection as a blueprint to strengthen subsequent submissions. Each denial became a roadmap. This iterative approach — submit, receive objections, address objections precisely, resubmit — ultimately produced over 13,000 public submissions, the largest volume ever received by Australian regulators for any medicine rescheduling, with 98% supporting approval.
• •Advisory Panel as Credibility Infrastructure: Without medical credentials, de Jong built a 75-person global advisory panel of researchers, clinicians, and scientists including David Nutt, Robin Carhart-Harris, and Roland Griffiths. She initiated contact through conference attendance, cold outreach, and warm introductions — each new member facilitating the next. This panel gave the organization scientific legitimacy when presenting to governments, regulators, and clinicians, directly countering the "who are these non-medical people" objection that repeatedly surfaced from the research community.
• •Unexpected Skill as a Door-Opener: De Jong secured a speaking slot at the Usona Institute conference in Madison, Wisconsin — where she met key scientific allies — partly by offering to sing at the event. This unconventional value-add differentiated her from other outreach requests and created a warm audience before any formal pitch. The lesson: when approaching gatekeepers who receive constant requests, leading with an unexpected, genuine skill or contribution can convert a cold ask into an accepted invitation.
• •Emotional Testimony Paired with Scientific Data: At a pivotal TGA presentation, de Jong structured the session so that a widow whose husband died after being denied access to psychedelic therapy spoke immediately before Professor David Nutt's scientific presentation. An expected audience of 10–15 TGA employees drew 140 attendees. The combination of personal loss made concrete and peer-reviewed evidence delivered sequentially produced a room-wide emotional response that preceded the eventual approval decision three months later.
• •Train the Ecosystem Before Approval Arrives: Mind Medicine Australia launched a certificate program in psychedelic-assisted therapy in 2021 — two years before rescheduling — and had trained over 750 clinicians by the time prescribing became legal. This meant that when approval arrived, a network of psychiatrists, psychologists, nurses, and counselors was already prepared to apply for authorized prescriber status. The result: 120 authorized prescribing psychiatrists and over 400 treated patients within roughly two years of legalization.
• •Payor Recruitment as a Parallel Track: Rather than waiting for clinical rollout to stabilize before approaching insurers and government agencies, Mind Medicine Australia engaged the Department of Veterans Affairs, the National Disability Insurance Scheme, and Medibank (Australia's largest private insurer) from early in the campaign. Medibank now covers most treatment costs for eligible gold members. The economic argument used: upfront treatment costs of approximately AUD 25,000 generate lifetime savings exceeding AUD 100,000 per patient, based on MAPS economic modeling conducted prior to Australian legalization.
• •Real-World Evidence Registry as Regulatory Leverage: To sustain and expand the program post-approval, Mind Medicine Australia funded an independent patient outcomes registry at Australian National University, with no editorial influence over the data. The registry tracks patient baseline scores, post-treatment outcomes, and adverse events. With 60–80% remission rates reported versus 10–15% for existing PTSD and depression treatments, this dataset provides the government with cost-savings evidence and safety data — the two variables most likely to influence future regulatory decisions and public funding commitments.